Incidence of infections and cytarabine-related adverse events according to HDAC schedule
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . |
|---|---|---|---|
| Microbiologically documented bacteremia, n (%) | |||
| Cycle 1 | 14 (15.2) | 29 (22.5) | .18 |
| Cycle 2 | 14 (17.5) | 28 (24.8) | .23 |
| Cycle 3 | 12 (25.0) | 25 (32.5) | .37 |
| Documented Streptococcus sp. bacteremia during postremission treatment, n (%) | 1 (1.1) | 12 (9.3) | .01 |
| IFI requiring systemic antifungal therapy, n (%) | |||
| Cycle 1 | 4 (4.3) | 2 (1.6) | .23 |
| Cycle 2 | 1 (1.3) | 4 (3.5) | .40 |
| Cycle 3 | 1 (2.1) | 2 (2.6) | 1 |
| Virus requiring systemic antiviral therapy, n (%) | |||
| Cycle 1 | 0 (0.0) | 2 (1.6) | .51 |
| Cycle 2 | 1 (1.3) | 3 (2.7) | .64 |
| Cycle 3 | 0 (0.0) | 1 (1.3) | 1 |
| Grade 3-4 mucositis, n (%) | |||
| Cycle 1 | 0 (0.0) | 5 (3.9) | .15 |
| Cycle 2 | 0 (0.0) | 1 (0.9) | 1 |
| Cycle 3 | 0 (0.0) | 0 (0.0) | — |
| Grade 1-2 erythema, n (%)* | |||
| Cycle 1 | 9 (9.8) | 20 (15.5) | .21 |
| Cycle 2 | 6 (7.5) | 5 (4.4) | .53 |
| Cycle 3 | 4 (8.3) | 2 (2.6) | .20 |
| Acute cerebellar syndrome, n (%) | |||
| Cycle 1 | 2 (2.2) | 2 (1.6) | 1 |
| Cycle 2 | 0 (0.0) | 0 (0.0) | — |
| Cycle 3 | 0 (0.0) | 0 (0.0) | — |
| . | HDAC-123, n = 92 (41.6%) . | HDAC-135, n = 129 (58.4%) . | P . |
|---|---|---|---|
| Microbiologically documented bacteremia, n (%) | |||
| Cycle 1 | 14 (15.2) | 29 (22.5) | .18 |
| Cycle 2 | 14 (17.5) | 28 (24.8) | .23 |
| Cycle 3 | 12 (25.0) | 25 (32.5) | .37 |
| Documented Streptococcus sp. bacteremia during postremission treatment, n (%) | 1 (1.1) | 12 (9.3) | .01 |
| IFI requiring systemic antifungal therapy, n (%) | |||
| Cycle 1 | 4 (4.3) | 2 (1.6) | .23 |
| Cycle 2 | 1 (1.3) | 4 (3.5) | .40 |
| Cycle 3 | 1 (2.1) | 2 (2.6) | 1 |
| Virus requiring systemic antiviral therapy, n (%) | |||
| Cycle 1 | 0 (0.0) | 2 (1.6) | .51 |
| Cycle 2 | 1 (1.3) | 3 (2.7) | .64 |
| Cycle 3 | 0 (0.0) | 1 (1.3) | 1 |
| Grade 3-4 mucositis, n (%) | |||
| Cycle 1 | 0 (0.0) | 5 (3.9) | .15 |
| Cycle 2 | 0 (0.0) | 1 (0.9) | 1 |
| Cycle 3 | 0 (0.0) | 0 (0.0) | — |
| Grade 1-2 erythema, n (%)* | |||
| Cycle 1 | 9 (9.8) | 20 (15.5) | .21 |
| Cycle 2 | 6 (7.5) | 5 (4.4) | .53 |
| Cycle 3 | 4 (8.3) | 2 (2.6) | .20 |
| Acute cerebellar syndrome, n (%) | |||
| Cycle 1 | 2 (2.2) | 2 (1.6) | 1 |
| Cycle 2 | 0 (0.0) | 0 (0.0) | — |
| Cycle 3 | 0 (0.0) | 0 (0.0) | — |
IFI, invasive fungal infection.
No grade 3-4 erythema.